Janssen Announces FDA Accelerated Approval for SIRTURO As Therapy to Treat Adolescents With Pulmonary Multidrug-Resistant Tuberculosis
August 09, 2019
August 09, 2019
TITUSVILLE, New Jersey, Aug. 9 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
- Label Expansion Marks Important Milestone in Johnson & Johnson's Pediatric Research And Development Program For Bedaquiline
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for SIRTURO(R . . .
* * *
- Label Expansion Marks Important Milestone in Johnson & Johnson's Pediatric Research And Development Program For Bedaquiline
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for SIRTURO(R . . .